Major Chest Procedures with CC DRG Reimbursement Guide

Summary & Overview

Major Chest Procedures with CC: Inpatient Reimbursement Overview

DRG 164 encompasses major chest surgical procedures performed on inpatient beneficiaries when a Complication or Comorbidity is present; these are higher-acuity thoracic operations with increased resource needs. Correct classification matters for inpatient reimbursement because the Complication or Comorbidity status increases the assigned Medicare Severity Diagnosis-Related Group and thereby influences Centers for Medicare & Medicaid Services payment.

Major Chest Procedures with CCDRG Major Chest Procedures with CCDRG 164Diagnosis-Related GroupInpatient ReimbursementMedicareThoracic SurgeryCardiothoracicLung ResectionThoracotomy

DRG 164 Overview

DRG 164 covers major thoracic surgical procedures on the chest with an accompanying Complication or Comorbidity, including extensive resections, complex thoracotomies, and procedures on the mediastinum or pleura. These cases typically involve significant intraoperative resources and postoperative management that increase hospital resource use. For Medicare inpatient payment, the presence of a Complication or Comorbidity elevates the classification and affects the payment relative to cases without such comorbid conditions. Accurate documentation and coding of operative procedures and concurrent conditions determine appropriate Medicare Severity Diagnosis-Related Group assignment and reimbursement.

National Payment Rates

Across payers the observed rate range spans from about $1.1K (BCBS 25th percentile) up to $95K (Anthem max), with mean payments varying widely by payer. Anthem and Aetna show higher median and upper-tail values while BCBS and Cigna report lower medians, producing the widest spread between the highest max (Anthem $95K) and lower-mid payer medians. See the table and chart below for payer-specific percentiles and distribution details.

Mean Rates by Payer — National — DRG 164

The CMS 2023 data reflect national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($24.6k), average submitted covered charges ($122.5k), average Medicare payment ($19.8k), and total discharges (15.1k).

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

For DRG 164, mean rates in Alaska range from $39K (Anthem and Blue Cross Blue Shield) up to $61K (Cigna), a substantial spread across payers. The most notable deviation from national averages is Cigna’s higher mean of $61K compared with typical national means, while Anthem/Blue Cross Blue Shield sit well below national medians. See the table and chart below for payer-specific detail.

Key Insights for Alaska

Anthem is the lowest-paying payer at $39K while Cigna is the highest-paying payer at $61K, representing the largest within-state spread.
Alaska’s Cigna mean of $61K sits meaningfully above national means for major payers, while Anthem/BCBS at $39K are notably below national medians, indicating a bimodal distribution versus national averages.

Clinical Trials

Trials of perioperative ventilatory strategies and respiratory support protocols: randomized or pragmatic studies that compare different intraoperative and immediate postoperative ventilator settings, use of lung-protective ventilation, or timing and criteria for invasive versus noninvasive respiratory support in adults undergoing major thoracic surgery with complications (eg, patients with preexisting COPD, pneumonia, or acute respiratory failure). These studies focus on the acute intra- and early post-op care period to reduce pulmonary complications, duration of mechanical ventilation, and ICU stays, and are relevant because ventilator management directly affects morbidity, LOS, and resource use for DRG 164 patients. Payers and providers use this evidence to optimize protocols that can lower complication-driven costs and readmission risk.
Comparative effectiveness trials of surgical approaches and perioperative bundles for complex chest procedures: prospective cohort studies or randomized trials comparing open thoracotomy versus minimally invasive techniques (eg, VATS/robotic) combined with standardized enhanced recovery pathways in patients requiring major chest operations complicated by comorbidities (eg, cardiac disease, obesity, or infection). These trials evaluate outcomes such as complication rates, transfusion needs, length of stay, and functional recovery in a higher-risk, CC-bearing population, informing which approach yields better clinical and economic outcomes for the inpatient episode. Results are important to clinicians choosing operative strategy and to payers assessing value-based reimbursement for high-cost procedures grouped under this DRG.
Post-discharge outcomes and readmission prevention studies targeting high-risk survivors of major chest procedures: observational cohorts or interventional trials testing post-acute care interventions (eg, structured transitional care, home-based respiratory therapy, or remote monitoring) in patients discharged after complicated thoracic surgery with comorbid conditions. These studies address 30- and 90-day readmissions, late pulmonary or infectious complications, functional status, and costs of post-acute care among DRG 164 patients, providing evidence on which discharge planning and follow-up models most reduce readmissions and downstream expenditures. Such research matters to hospitals and payers aiming to improve quality metrics and control total episode spending.

Respiratory System Diagnosis with Ventilator Support >96 Hours: Inpatient Reimbursement Overview

189-PULMONARY-EDEMA-AND-RESPIRATORY-FAILURE

Pulmonary Edema and Respiratory Failure: Inpatient Reimbursement Overview

168-OTHER-RESPIRATORY-SYSTEM-O-R-PROCEDURES-WITHOUT-CC-MCC

Other Respiratory System O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

185-MAJOR-CHEST-TRAUMA-WITHOUT-CC-MCC

Major Chest Trauma without CC/MCC: Inpatient Reimbursement Overview

204-RESPIRATORY-SIGNS-AND-SYMPTOMS

Respiratory Signs and Symptoms: Inpatient Reimbursement Overview

193-SIMPLE-PNEUMONIA-AND-PLEURISY-WITH-MCC

Simple Pneumonia and Pleurisy with MCC: Inpatient Reimbursement Overview

191-CHRONIC-OBSTRUCTIVE-PULMONARY-DISEASE-WITH-CC

Chronic Obstructive Pulmonary Disease with CC: Inpatient Reimbursement Overview

196-INTERSTITIAL-LUNG-DISEASE-WITH-MCC

Interstitial Lung Disease with MCC: Inpatient Reimbursement Overview

180-RESPIRATORY-NEOPLASMS-WITH-MCC

Respiratory Neoplasms with MCC: Inpatient Reimbursement Overview

200-PNEUMOTHORAX-WITH-CC

Pneumothorax with CC: Inpatient Reimbursement Overview

Showing 1–10 of 40

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$25K	$120K	$20K	15K